BACKGROUND. There have been no US studies published on the effectiveness, safety, time
to bleeding, and acceptability of misoprostol administered by vagina at home and repeated …

BACKGROUND: A combination of mifepristone and misoprostol provides an effective
method of medical abortion for early pregnancy. This is the first randomized trial comparing …

Aim The aim of the present study was to investigate the safety and efficacy of low‐dose
mifepristone combined with self‐administered misoprostol for termination of early …

This study assessed the efficacy and side effects of first trimester medical abortion using
mifepristone and vaginally administered misoprostol. Medical abortion was first introduced …

BACKGROUND: The dose of mifepristone approved by most government agencies for
medical abortion is 600 mg. Our aim was to summarize extant data on the effectiveness and …

OBJECTIVE: To assess the potential advantages of combined mifepristone–misoprostol
versus misoprostol-only for early medical abortion. METHODS: A double-blind randomized …

BACKGROUND: From 2001 to March 2006, Planned Parenthood Federation of America
(Planned Parenthood) health centers throughout the United States provided medical …

In the first 18 months since mifepristone was approved by the Food and Drug Administration
(FDA) for use with misoprostol for early medical abortion, approximately 80,000 women …

BACKGROUND: Vaginal misoprostol has been shown to be an effective single agent for
medical abortion. This randomized, double-blinded, placebo-controlled trial compared a …

Objective: To describe the use of mifepristone in combination with buccal misoprostol in
women undergoing an early medical abortion (EMA) in Australia. Design, setting and …